Skip To Main Content
Elizabeth Jaffee on Muck Rack

Elizabeth Jaffee

As seen in: Nature, Fortune, The BMJ, Genome Medicine, Science Magazine, The New England Journal of Medicine, Cell Press, The Lancet, Healio, HemOnc Today and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elizabeth

Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial

|
By Hejia Wang, Amanda L Huff, S. Haldar, Maureen Berg, Christopher Thoburn, Thatcher Heumann, Robert A. Anders, Benjamin Barrett, Katherine M. Bever, Michael Pishvaian, Valerie Lee, Dung T Le, Eric Christenson Verified, Marina Baretti, Mark Yarchoan, Daniel A. Laheru, Amy Thomas, Jennifer N. Durham, Jiayun Lu, Hao Wang, Elizabeth Jaffee, Nilofer S. Azad, Neeha Zaidi, Julie M. Nauroth
| Nature Verified
Abstract Immune checkpoint inhibitors (ICIs) have limited activity in mismatch repair proficient or microsatellite stable (MMRp/MSS) colorectal cancer (CRC). KRAS mutations, present in approximately 40% of these cancers, can generate neoantigens that are targets for therapeutic vaccines.
Open in Who Shared Issue with article?

The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study

|
By Valerie Lee, Christina Rodriguez, Junke Wang, Hanfei Qi, Rose Parkinson, Thomas McPhaul, Jennifer N. Durham, Amy Hacker-Prietz, Amol K. Narang, Dung T Le, Ana De Jesus, Michael Pishvaian, Eric Christenson Verified, Elizabeth Thompson, Robert A. Anders, Arsen Osipov, Matthew B. Weiss, William Burns, Richard Burkhart Verified, Kelly J Lafaro, Jin He, Christopher L Wolfgang, Elizabeth A. Sugar, Joseph M. Herman, Elizabeth Jaffee, Hao Wang, Daniel A. Laheru, Lei Zheng, Apoorvaa S. Sachidanand, Beth Onners
| Nature Verified
Abstract In this Phase II study (NCT02648282) of locally advanced pancreatic cancer (LAPC), 58 patients were enrolled and intended for an immunotherapy including GM-CSF-secreting allogeneic pancreatic cancer vaccine (GVAX) and pembrolizumab and stereotactic body radiation therapy (SBRT) following standard chemotherapy. Fifty-four evaluable patients received two cycles of immunotherapy and SBRT and reassessed for resectability.
Open in Who Shared Issue with article?

A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial - Nature Medicine

|
By Allison Kirk, Kayla J. Bendinelli, Won Jin Ho, Samir Adhikari, Balaji Sundararaman, Hao Wang, Hanfei Qi, Sarah Shin, Alexei Vega Hernández, Chris Thoburn, Neeha Zaidi, Elizabeth Jaffee, Paul Thomas
| Nature Verified
Abstract Fibrolamellar hepatocellular carcinoma (FLC) is a rare form of liver cancer affecting children and young adults that is driven by a chimeric protein, DNAJ-PKAc. The development of molecular inhibitors of DNAJ-PKAc has been hampered by unacceptable on-target toxicity, but the chimera results in a tumor-specific antigen (neoantigen) that may be targeted immunologically.
Open in Who Shared Issue with article?
See all 36 licensed articles (38 Total)